
|Videos|August 30, 2021
Dr. Seth weighs in on onabotulinumtoxinA injections in patients with complex medical backgrounds
Author(s)Urology Times staff
“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.
Advertisement
In this video, Jai Seth, MD, discusses the background and objectives of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5


















